# Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer

> **NCT02012634** · — · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 340 (estimated)

## Conditions studied

- Breast Cancer
- Capecitabine
- Triple Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02012634
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2015-12
- **Final completion:** 2018-12
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2014-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02012634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02012634, "Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02012634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*